Hjem › Myelodysplastiske syndromer › Kansas
Myelodysplastiske syndromer kliniske forsøg i Kansas
5 studier for Myelodysplastiske syndromer søger deltagere på steder i Kansas.
Byer i Kansas
Officiel studietekst (engelsk)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- og 7 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
- University of Kansas Medical Center Research Institute, Inc., Kansas City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT06146257Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- University of Kansas Cancer Center, Westwood
RekruttererFase 1
Alder 18 til 65 · Alle køn · Opdateret 25. mar. 2026 · NCT03533816Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
- University of Kansas Cancer Center, Fairway
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. jun. 2020 · NCT04167696Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.